15.12.2025
SL Insight Newsletter #11
Switzerland as a price anchor in GENEROUS
Marcel Boller
On December 19, the White House announced further MFN agreements and explicitly mentioned Genentech (Roche) and Novartis. This is relevant for Switzerland because prices in the specialty list are easier to use in international benchmarks as clear, package-specific price anchors.
Key points for Switzerland
- MFN/GENEROUS increase the visibility of "small" markets with clear list prices, such as Switzerland.
- Launch and price range decisions must be more closely aligned with international comparability before SL applications are submitted.
- In BAG discussions, there is increasing pressure to document pricing logic and budgets consistently and at an early stage.
